Telmisartan 40 mg

DRUG4 trials

Sponsors

Boehringer Ingelheim

Conditions

Coronary ArteriosclerosisHypertension

Phase 3

Combination of Telmisartan 40 mg Plus Hydrochlorothiazide (HCTZ) 12.5 mg vs. Telmisartan 40 mg Alone in Patients With Essential Hypertension Who Fail to Respond Adequately to Telmisartan Monotherapy

CompletedNCT00144222

Boehringer IngelheimHypertension

Start: 2005-01-31End: 2005-08-31Updated: 2013-11-05

Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension

CompletedNCT00281580

Boehringer IngelheimHypertension

Start: 2006-04-30Updated: 2014-03-27

Trial of Telmisartan 80 mg/HCTZ 12.5 mg and Telmisartan 40 mg/HCTZ 12.5 mg in Patients With Hypertension

CompletedNCT00326768

Boehringer IngelheimHypertension

Start: 2006-05-31End: 2007-08-31Updated: 2017-12-28

Phase 4

Inflammation and Coronary Artery Disease: Role of AT1-Receptor Antagonism

CompletedNCT00274144

Boehringer IngelheimCoronary Arteriosclerosis, Hypertension

Start: 2001-12-31End: 2004-05-31Target: 42Updated: 2013-11-01

Related Papers

Low-Dose Triple Antihypertensive Combination Therapy in Patients with Hypertension: A Randomized, Double-Blind, Phase II Study

Drug Design Development and Therapy2020-12-0125 citations